Sanofi's antibody riliprubart has received orphan drug designation from Japan's MHLW for its potential to treat CIDP.

Sanofi (NASDAQ:SNY) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 30, Sanofi (NASDAQ:SNY) announced that ...

Sanofi (NASDAQ:SNY) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 25, Sanofi (NASDAQ:SNY) ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy. Two phase 3 studies are currently underway testing riliprubart in peopl ...

Riliprubart is an immunoglobulin G4 humanized antibody that is designed to selectively inhibit activated C1s in the classical complement pathway of the innate immune system.

Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active antibody-mediated rejection in kidney transplant recipients Riliprubart was also designated orphan ...

Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational drug, riliprubart, for the treatment of antibody-mediated rejection (AMR) in solid organ transplantation.

Riliprubart was also designated orphan drug for the investigational use in chronic inflammatory demyelinating polyneuropathy in the US and EU ...

Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and ...

Riliprubart is being evaluated in a phase 2 trial for the prevention and treatment of antibody-mediated rejection. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ...